SYDNEY, April 6, 2022 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today released 2021 industry-wide Veeva Pulse data that shows the continued growth of digital engagement across the Asia Pacific* life sciences industry. Since the start of the COVID-19 pandemic, digital communication between biopharmas and healthcare professionals (HCPs) has steadily increased in this region. From March 2020 to August 2021, Veeva customers increased rep-sent emails by 295 percent while maintaining high open rates at 41 percent.
"COVID-19 has accelerated the shift to digital," said Shafi Hussain, Asia business consulting lead, Veeva Systems. "We've seen evolving requirements and changing preferences for the ways that HCPs want to engage with field reps."
"Key, useful messages prompt HCPs to read emails, and we anticipate this level of digital engagement will remain strong with relevant content," Hussain continued. "Establishing a strong digital presence as well as keeping on top of evolving channel innovation will help companies to find new ways of differentiating themselves."
More emails sent, higher open rates and increased meetings
Measuring APAC customer engagement, Veeva Pulse monitors email volume of activity and open rates:
Similarly, the remote meeting volume has increased since pre-COVID:
Veeva Pulse aggregates Veeva customer engagement data across the pharmaceutical industry and is used for benchmarking and identifying trends. Available data spans across 6 continents, 161 countries and over 350 customers.
* The Asia Pacific data includes Australia, New Zealand, South-East Asia and Korea. |
Additional Information
For more on Veeva Business Consulting, visit: veeva.com/ap/services/business-consulting-services/
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.